Loading
Life sciences · Journal article
Journal of Medical Economics · October 17, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Aims To examine all-cause and myelosuppressive event (MYSPE)-related healthcare resource utilization and costs among patients with small cell lung cancer (SCLC) in the United States treated with second-line therapies.Materials and Methods This retrospective cohort study of the Optum Market Clarity database included adult patients with SCLC who completed platinum-based first-line induction therapy and initiated second-line treatment (1 January 2020 to 31 May 2023); second-line treatment initiation was the index date. Patients were continuously enrolled for at least 1 month after the index date. Total standardized all-cause and MYSPE-related costs were calculated. Adjusted 12‑month costs were estimated using Lin’s weighted regression.Results The final analysis included 1,063 patients across 5 treatment cohorts: lurbinectedin monotherapy (N = 350), platinum-based chemotherapy (with any agent except lurbinectedin) (N = 249), immuno-oncology therapy (without lurbinectedin, topotecan, or platinum) (N = 154), topotecan-based therapy (without lurbinectedin or platinum) (N = 138), and other combinations (N = 172). Lurbinectedin monotherapy was associated with fewer MYSPEs than chemotherapies; mean MYSPE-related per-patient per-month costs were $1,407 with lurbinectedin monotherapy compared to $1,791 with platinum-based therapy and $2,314 with topotecan-based therapy. Mean unadjusted all-cause per-patient per-month costs were $24,274 in the lurbinectedin monotherapy cohort, $24,069 in the immuno-oncology therapy cohort, and $25,074 in the platinum-based therapy cohort. Mean adjusted 12-month all-cause costs of lurbinectedin monotherapy ($168,975) were lower than the costs for platinum-based ($249,914; p < 0.001) or immuno-oncology ($220,258; p = 0.004) therapies and higher than the costs for topotecan-based therapy ($121,865; p < 0.001).Limitations There may be misclassification or under-identification of SCLC cases due to the absence of specific SCLC diagnosis codes and potential underreporting of MYSPEs.Conclusions Lurbinectedin monotherapy was associated with decreased all-cause healthcare costs compared to platinum-based and immuno-oncology therapies, but not topotecan-based therapy, and decreased MYSPEs and MYSPE-related costs compared with chemotherapies.